肾移植患者难治性移植后淋巴细胞增生性疾病的嵌合抗原受体T细胞疗法 - Suppr

Suppr

超能文献

CAR T-Cell Therapy for Refractory Posttransplantation Lymphoproliferative Disorder in a Kidney Transplant Patient.

作者信息

Guy Pierre, Marion Olivier, Oberic Lucie, Darres Amandine, Cointault Olivier, Del Bello Arnaud, Kamar Nassim

机构信息

Department of Nephrology and Organ Transplantation, Toulouse University Hospital, Toulouse, France.

Department of Hematology, IUCT, Toulouse University Hospital, Toulouse, France.

出版信息

Transplant Direct. 2024 Feb 26;10(3):e1584. doi: 10.1097/TXD.0000000000001584. eCollection 2024 Mar.

DOI:10.1097/TXD.0000000000001584

PMID:38414975

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10898664/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35c2/10898664/b7e76955605d/txd-10-e1584-g001.jpg

相似文献

CAR T-Cell Therapy for Refractory Posttransplantation Lymphoproliferative Disorder in a Kidney Transplant Patient.

Transplant Direct. 2024 Feb 26;10(3):e1584. doi: 10.1097/TXD.0000000000001584. eCollection 2024 Mar.

CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder.

Am J Transplant. 2021 Feb;21(2):809-814. doi: 10.1111/ajt.16367. Epub 2020 Dec 5.

Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD).

Hum Vaccin Immunother. 2023 Aug 1;19(2):2216116. doi: 10.1080/21645515.2023.2216116. Epub 2023 Jun 6.

Initial spontaneous remission of posttransplantation Epstein Barr virus-related B-cell lymphoproliferative disorder of the skin in a renal transplant recipient: case report and review of the literature on cutaneous B-cell posttransplantation lymphoproliferative disease.

Am J Dermatopathol. 2002 Oct;24(5):414-22. doi: 10.1097/00000372-200210000-00008.

Kidney Transplant T Cell-Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report.

Am J Kidney Dis. 2022 May;79(5):760-764. doi: 10.1053/j.ajkd.2021.07.012. Epub 2021 Aug 27.

Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series.

Bone Marrow Transplant. 2021 May;56(5):1031-1037. doi: 10.1038/s41409-020-01145-1. Epub 2020 Nov 23.

Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient.

Kidney Med. 2021 May 28;3(4):665-668. doi: 10.1016/j.xkme.2021.03.011. eCollection 2021 Jul-Aug.

Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.

Br J Haematol. 2023 Jul;202(2):248-255. doi: 10.1111/bjh.18828. Epub 2023 May 2.

Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.

Front Oncol. 2021 Sep 16;11:726134. doi: 10.3389/fonc.2021.726134. eCollection 2021.

Posttransplantation lymphoproliferative disorder in cardiac transplant allografts.

Ann Thorac Surg. 1997 Dec;64(6):1822-4. doi: 10.1016/s0003-4975(97)01044-8.

引用本文的文献

Nephrology's Next Frontier: Expanding the Reach of CAR T-Cell Therapy for Refractory Lupus Nephritis and Beyond.

Indian J Nephrol. 2025 Jul-Aug;35(4):456-459. doi: 10.25259/IJN_274_2024. Epub 2024 Dec 11.

Application of novel CAR technologies to improve treatment of autoimmune disease.

Front Immunol. 2024 Oct 9;15:1465191. doi: 10.3389/fimmu.2024.1465191. eCollection 2024.

本文引用的文献

Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed/refractory solid organ transplant-related PTLD.

Br J Haematol. 2023 Jul;202(2):248-255. doi: 10.1111/bjh.18828. Epub 2023 May 2.

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.

Blood Adv. 2023 Jun 27;7(12):2872-2883. doi: 10.1182/bloodadvances.2022009019.

Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD.

JACC CardioOncol. 2022 Dec 20;4(5):713-716. doi: 10.1016/j.jaccao.2022.09.002. eCollection 2022 Dec.

CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review.

Curr Res Transl Med. 2021 Oct;69(4):103304. doi: 10.1016/j.retram.2021.103304. Epub 2021 Jul 22.

Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.

Cell Transplant. 2021 Jan-Dec;30:963689721996649. doi: 10.1177/0963689721996649.

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.

Blood. 2021 Jun 10;137(23):3272-3276. doi: 10.1182/blood.2020008865.

Safety of CAR T-cell therapy in kidney transplant recipients.

Blood. 2021 May 6;137(18):2558-2562. doi: 10.1182/blood.2020008759.

A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant.

Kidney Int. 2021 Jul;100(1):196-205. doi: 10.1016/j.kint.2020.12.015. Epub 2020 Dec 24.

Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series.

Bone Marrow Transplant. 2021 May;56(5):1031-1037. doi: 10.1038/s41409-020-01145-1. Epub 2020 Nov 23.

CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder.

Am J Transplant. 2021 Feb;21(2):809-814. doi: 10.1111/ajt.16367. Epub 2020 Dec 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验